Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Fabre

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
The Journal of Molecular Diagnostics : JMD|May 23, 2018
Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 SamplesAntoine Legras, Marc Barritault, Anne Tallet, et al.
Oncoimmunology|February 5, 2019
Circulating NKp46<sup>+</sup> Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung CancerEmilie Picard, Yann Godet, Caroline Laheurte, et al.
Ebiomedicine|October 23, 2021
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY studyPascaline Boudou-Rouquette, Jennifer Arrondeau, Claire Gervais, et al.
Oncogene|August 15, 2024
PrP<sup>C</sup> controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-upClaire Lailler, Audrey Didelot, Simon Garinet, et al.
Lung Cancer (Amsterdam, Netherlands)|December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohortAurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.
Journal for Immunotherapy of Cancer|March 11, 2021
CXCR6 deficiency impairs cancer vaccine efficacy and CD8<sup>+</sup> resident memory T-cell recruitment in head and neck and lung tumorsSoumaya Karaki, Charlotte Blanc, Thi Tran, et al.
Cancer Medicine|June 15, 2019
NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomasCamille Tlemsani, Nicolas Pécuchet, Aurelia Gruber, et al.
Nature Communications|May 25, 2017
Induction of resident memory T cells enhances the efficacy of cancer vaccineMevyn Nizard, Hélène Roussel, Mariana O Diniz, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancerEdouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, et al.
Kidney International Reports|February 23, 2026
Immune Profiling Identifies High-Risk Neutrophil-Rich Subtype in Checkpoint Inhibitor NephritisIdris Boudhabhay, Helene Lazareth, Julie Oniszczuk, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
The Journal of Molecular Diagnostics : JMD|May 23, 2018
Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 SamplesAntoine Legras, Marc Barritault, Anne Tallet, et al.
Oncoimmunology|February 5, 2019
Circulating NKp46<sup>+</sup> Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung CancerEmilie Picard, Yann Godet, Caroline Laheurte, et al.
Ebiomedicine|October 23, 2021
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY studyPascaline Boudou-Rouquette, Jennifer Arrondeau, Claire Gervais, et al.
Oncogene|August 15, 2024
PrP<sup>C</sup> controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-upClaire Lailler, Audrey Didelot, Simon Garinet, et al.
Lung Cancer (Amsterdam, Netherlands)|December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohortAurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.
Journal for Immunotherapy of Cancer|March 11, 2021
CXCR6 deficiency impairs cancer vaccine efficacy and CD8<sup>+</sup> resident memory T-cell recruitment in head and neck and lung tumorsSoumaya Karaki, Charlotte Blanc, Thi Tran, et al.
Cancer Medicine|June 15, 2019
NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomasCamille Tlemsani, Nicolas Pécuchet, Aurelia Gruber, et al.
Nature Communications|May 25, 2017
Induction of resident memory T cells enhances the efficacy of cancer vaccineMevyn Nizard, Hélène Roussel, Mariana O Diniz, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancerEdouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, et al.
Kidney International Reports|February 23, 2026
Immune Profiling Identifies High-Risk Neutrophil-Rich Subtype in Checkpoint Inhibitor NephritisIdris Boudhabhay, Helene Lazareth, Julie Oniszczuk, et al.
Pageof 8